tirzepatide surmount-1 trial weight loss non-diabetic for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity surmount-1 tirzepatide non-diabetic obesity weight

Patients experiencing persistent gastrointestinal side effects that interfere with daily activities or nutritional intake may benefit from extending the duration at each dose level beyond the minimum four weeks before attempting further escalation

References 1.Choquet-Kastylevsky G, Vial T, Descotes J

Like natural GLP-1, semaglutide targets GLP-1 receptors located throughout your gastrointestinal tract, pancreas, and brain to: Slow down digestion Encourage the release of insulin after eating Reduce the amount of glucagon (sugar) that gets released after eating Send signals of satiety (fullness) to your brain Together, these effects help control both your blood sugar levels and your appetite

Research shows that up to 2540% of weight lost on GLP-1 medications can come from lean tissue (Nature Medicine, 2023)

We got responses through phone, in-app chat, and email, and the people we spoke with were polite and helpful